ID: ALA2431588

Max Phase: Preclinical

Molecular Formula: C26H30N4O5S

Molecular Weight: 510.62

Molecule Type: Small molecule

Representations

Canonical SMILES:  CCOc1cc(C(Nc2ccc(C(=N)N)cc2)C(=O)NS(=O)(=O)c2ccccc2)ccc1OC(C)C

Standard InChI:  InChI=1S/C26H30N4O5S/c1-4-34-23-16-19(12-15-22(23)35-17(2)3)24(29-20-13-10-18(11-14-20)25(27)28)26(31)30-36(32,33)21-8-6-5-7-9-21/h5-17,24,29H,4H2,1-3H3,(H3,27,28)(H,30,31)

Standard InChI Key:  TZTGDSJKKVVPPS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 510.62

Molecular Weight (Monoisotopic): 510.1937

AlogP: 3.81

#Rotatable Bonds: 11

Polar Surface Area: 143.60

Molecular Species: ZWITTERION

HBA: 7

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 3.97

CX Basic pKa: 12.50

CX LogP: 3.13

CX LogD: 3.13

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.23

Np Likeness Score: -0.98

References

1. Glunz PW, Zhang X, Zou Y, Delucca I, Nirschl AH, Cheng X, Weigelt CA, Cheney DL, Wei A, Anumula R, Luettgen JM, Rendina AR, Harpel M, Luo G, Knabb R, Wong PC, Wexler RR, Priestley ES..  (2013)  Nonbenzamidine acylsulfonamide tissue factor-factor VIIa inhibitors.,  23  (18): [PMID:23845220] [10.1016/j.bmcl.2013.06.027]

2. Glunz PW, Cheng X, Cheney DL, Weigelt CA, Wei A, Luettgen JM, Wong PC, Wexler RR, Priestley ES..  (2015)  Design and synthesis of potent, selective phenylimidazole-based FVIIa inhibitors.,  25  (10): [PMID:25881820] [10.1016/j.bmcl.2015.03.062]

Source

Source(1):

• Scientific Literature